Last week, when the 15 minutes of fame, or rather infamy, of Turing Pharma CEO Martin Shkreli came and went following his now ill-fated attempt to boost the price of a toxoplasmosis drug by 5000%, we said two things: "Martin Shkreli's (who started his Wall Street career working for Jim Cramer, and apparently still owes the Lehman estate $2.3 million for a Put trade gone wrong) decision to disturb the fragile equilibrium in the biotech industry"and "now that Shkreli's 15 minutes of fame are over and his Twitter profile is now in "private" mode the attention should shift to the real villains – those truly big pharma companies, who do what Shkreli did but on a far vaster and grander, if less obvious, scale taking advantage of the price cushioning effects that Obamacare provides."

Today, this is precisely what happened, when as we reported previously Democrats on the House oversight committee sent a letter demanding that serial biotech rollup Valeant Pharmaceuticals should provide documents explaining hefty price increases for two heart drugs.